Clinical Trials Logo

Clinical Trial Summary

Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR. Scientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures. A lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions.


Clinical Trial Description

Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR. Scientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures. A lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04592003
Study type Observational
Source University Hospital, Limoges
Contact Jérémie Jacques, Dr
Phone 05 55 05 87 72
Email jeremie.jacques@chu-limoges.fr
Status Recruiting
Phase
Start date January 1, 2020
Completion date December 19, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05536089 - ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation
Active, not recruiting NCT04392479 - TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. Phase 3
Not yet recruiting NCT05577143 - Blood Screening for Adult Colorectal Cancer
Active, not recruiting NCT05585866 - Propofol and Sevoflurane Anesthesia in Colorectal Cancer Surgery: Incidence of Acute Kidney Injury
Recruiting NCT05573022 - Impact of a Patient Decision Aid Intervention N/A
Completed NCT02931825 - Identification of High Risk People for Colorectal Cancer and Evaluation of a Specific Surveillance System N/A
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Not yet recruiting NCT05791747 - Representations, Beliefs and Attitudes Towards Hypnosis in Patients Followed for Colorectal Cancer
Recruiting NCT05830097 - A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06324409 - ImmigrantScreen Telephone Reminder Trial in Colorectal Cancer Screening N/A
Recruiting NCT04258813 - Onco-primary Care Networking to Support TEAM-based Care N/A
Active, not recruiting NCT05939440 - Interventions to Decrease Financial Toxicity N/A
Completed NCT04548765 - Evaluation of Letters Promoting Colorectal Cancer Testing N/A
Recruiting NCT04189055 - Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. Phase 2
Withdrawn NCT04345952 - Calm for Cancer Patients Receiving Chemotherapy N/A
Completed NCT04280393 - Effectiveness and Safety of the Colonoscopy Assisted by Endocuff vs. Standard in the Colorectal Cancer Screening N/A
Not yet recruiting NCT06231576 - Digital Home-Based Prehabilitation Before Surgery N/A
Recruiting NCT04874883 - Effect of the Use of Symbiotics in Patients With Colon Cancer Phase 4
Completed NCT04074460 - Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study Phase 4
Not yet recruiting NCT06191185 - IMProving Adherence to Colonoscopy Through Teams and Technology N/A